(OMCL) Omnicell - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68213N1090

OMCL: Medication Management, Automation Solutions, Dispensing Systems, Pharmacy Automation, Inventory Management, Patient Engagement, Clinical

Omnicell, Inc. (NASDAQ:OMCL) is a global leader in medication management and healthcare technology, offering a comprehensive suite of solutions designed to optimize clinical workflows, improve patient safety, and enhance operational efficiency. The company provides automation, data analytics, and professional services to healthcare systems, pharmacies, and post-acute care facilities worldwide. Its product portfolio includes the XT Series automated dispensing systems, which streamline medication and supply management in nursing units and clinical areas. Omnicell also offers specialized dispensing systems tailored for hospitals, health systems, and post-acute care settings. Additionally, the company provides central pharmacy dispensing services, IV compounding solutions, and turnkey specialty pharmacy programs that assist health systems in establishing and managing entity-owned specialty pharmacies, including payer contracting, staffing, and 340B program administration.

Omnicell’s inventory optimization services leverage predictive and prescriptive analytics, benchmarking tools, and clinical resources to provide medication inventory visibility and improve decision-making. The company also offers patient engagement and clinical solutions, as well as financial tools to enhance care coordination and operational outcomes. Its medication adherence solutions include single-dose automation, automated filling equipment, and blister card packaging supplies. Software solutions guide users through manual filling processes, ensuring accuracy and efficiency. Omnicell further supports its clients with professional services such as technology installation, program management, customer education, and change management. Technical services include post-installation support, maintenance, and access to software upgrades. The company also operates in international markets, providing retail pharmacy and hospital automation solutions outside the U.S.

Omnicell, Inc. was founded in 1992 and was formerly known as Omnicell Technologies, Inc. before changing its name in 2001. Headquartered in Fort Worth, Texas, the company has established itself as a key player in the healthcare technology sector, focusing on innovative solutions to address the challenges of medication management and patient care. Web URL: https://www.omnicell.com

Ticker Symbol: OMCL Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Health Care Technology Average Volume 20d: 575153 Last Price: 31.38 SMA 20: 31.27 SMA 50: 34.15 SMA 200: 40.49 ATR: 1.40 Market Cap: 1470.89M USD P/E: 116.30 P/E Forward: 29.50 P/B: 1.18 P/S: 1.32 RoE: 1.01 3 Month Forecast: Based on and , Omnicell’s stock is expected to experience volatility within a narrow range. The SMA 20 and SMA 50 indicate a potential downtrend, while the SMA 200 suggests a longer-term bearish outlook. The ATR of 1.40 signals moderate price movement. Fundamentally, the high P/E ratio of 116.30 reflects elevated valuations, while the forward P/E of 29.50 indicates expectations of improved earnings. The P/S ratio of 1.32 aligns with industry averages, and the RoE of 1.01 highlights modest profitability. Overall, the stock may face headwinds in the near term but could stabilize as growth prospects materialize.

Additional Sources for OMCL Stock

OMCL Stock Overview

Market Cap in USD 1,470m
Sector Healthcare
Industry Health Information Services
GiC Sub-Industry Health Care Technology
IPO / Inception 2001-08-07

OMCL Stock Ratings

Growth Rating -47.1
Fundamental 19.2
Dividend Rating 0.0
Rel. Strength 4.4
Analysts 3.78/5
Fair Price Momentum 26.24 USD
Fair Price DCF 63.85 USD

OMCL Dividends

No Dividends Paid

OMCL Growth Ratios

Growth Correlation 3m -93.3%
Growth Correlation 12m 27.7%
Growth Correlation 5y -75.8%
CAGR 5y -15.31%
CAGR/Max DD 5y -0.18
Sharpe Ratio 12m -1.44
Alpha 2.85
Beta -0.070
Volatility 43.59%
Current Volume 567.5k
Average Volume 20d 575.5k
What is the price of OMCL stocks?
As of May 05, 2025, the stock is trading at USD 31.16 with a total of 567,516 shares traded.
Over the past week, the price has changed by +1.04%, over one month by -4.68%, over three months by -28.94% and over the past year by +3.94%.
Is Omnicell a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Omnicell is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 19.17 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of OMCL as of May 2025 is 26.24. This means that OMCL is currently overvalued and has a potential downside of -15.79%.
Is OMCL a buy, sell or hold?
Omnicell has received a consensus analysts rating of 3.78. Therefor, it is recommend to hold OMCL.
  • Strong Buy: 3
  • Buy: 1
  • Hold: 5
  • Sell: 0
  • Strong Sell: 0
What are the forecast for OMCL stock price target?
According to ValueRays Forecast Model, OMCL Omnicell will be worth about 28.3 in May 2026. The stock is currently trading at 31.16. This means that the stock has a potential downside of -9.05%.
Issuer Forecast Upside
Wallstreet Target Price 50.7 62.7%
Analysts Target Price 50.7 62.7%
ValueRay Target Price 28.3 -9.1%